Table 4. HFE genotype and metastasis rate based on sex of lung cancer patients at PSHMC.

Male		PSHMC LUAD (n = 23), n (%)	Metastasis, n (%)	Fisher’s exact test (WT HFE vs variant HFE)	PSHMC LUSC (n = 28), n (%)	Metastasis, n (%)	Fisher’s exact test (WT HFE vs variant HFE)
H63D HFE	CC	14 (60.9%)	7 (50.0%)	p = 0.0189	24 (85.7%)	10 (41.7%)	p = 0.0978
	CG or GG	9 (39.1%)	0 (0.0%)		4 (16.7%)	4 (100.0%)
C282Y HFE	GG	19 (82.6%)	4 (21.1%)	p = 0.0672	24 (85.7%)	11 (45.8%)	p = 0.5956
	GA or AA	4 (17.4%)	3 (75.0%)		4 (16.7%)	3 (75.0%)
Female		LUAD (n = 30), n (%)	Metastasis, n (%)	Fisher’s exact test (WT HFE vs variant HFE)	LUSC (n = 13), n (%)	Metastasis, n (%)	Fisher’s exact test (WT HFE vs variant HFE)
H63D HFE	CC	22 (73.3%)	3 (13.6%)	p = 0.0596	11 (84.6%)	2 (18.2%)	p = 1.0
	CG or GG	8 (26.7%)	4 (50.0%)		2 (15.4%)	0 (0.0%)
C282Y HFE	GG	27 (90.0%)	7 (25.9%)	p = 1.0	12 (92.3%)	2 (16.7%)	p = 1.0
	GA or AA	3 (10.0%)	0 (0.0%)		1 (7.7%)	0 (0.0%)

LUAD (lung adenocarcinoma)

LUSC (lung squamous cell carcinoma)